Log in

ProMIS Neurosciences Stock Forecast, Price & News

+0.00 (+1.12 %)
(As of 10/21/2020 03:50 PM ET)
Today's Range
Now: $0.10
50-Day Range N/A
52-Week Range
Now: $0.10
Volume108,537 shs
Average Volume133,116 shs
Market Capitalization$28.71 million
P/E RatioN/A
Dividend YieldN/A
ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platformÂProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AÃO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AÃO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company has a collaboration with BC Neuroimmunology to develop and commercialize proprietary diagnostic assays; and BC Neuroimmunology to develop and offer blood-based diagnostic tests for Alzheimer's diseases. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars

Industry, Sector and Symbol

Industry Commercial physical research
Phone416 847 6898



Sales & Book Value

Annual SalesN/A


Net Income$-5,570,000.00


Market Cap$28.71 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
+0.00 (+1.12 %)
(As of 10/21/2020 03:50 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARFXF News and Ratings via Email

Sign-up to receive the latest news and ratings for ARFXF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ProMIS Neurosciences (OTCMKTS:ARFXF) Frequently Asked Questions

When is ProMIS Neurosciences' next earnings date?

ProMIS Neurosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for ProMIS Neurosciences

Are investors shorting ProMIS Neurosciences?

ProMIS Neurosciences saw a drop in short interest during the month of September. As of September 30th, there was short interest totaling 10,000 shares, a drop of 92.7% from the September 15th total of 137,600 shares. Based on an average trading volume of 235,900 shares, the days-to-cover ratio is presently 0.0 days.
View ProMIS Neurosciences' Short Interest

Who are some of ProMIS Neurosciences' key competitors?

Who are ProMIS Neurosciences' key executives?

ProMIS Neurosciences' management team includes the following people:
  • Mr. Eugene Williams, Exec. Chairman (Age 61)
  • Dr. Elliot Goldstein, Pres, CEO & Director (Age 69)
  • Dr. Neil R. Cashman, Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
  • Mr. Daniel E. Geffken M.B.A., MBA, Chief Financial Officer (Age 63)
  • Dr. Johanne Kaplan, Chief Devel. Officer

What is ProMIS Neurosciences' stock symbol?

ProMIS Neurosciences trades on the OTCMKTS under the ticker symbol "ARFXF."

How do I buy shares of ProMIS Neurosciences?

Shares of ARFXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ProMIS Neurosciences' stock price today?

One share of ARFXF stock can currently be purchased for approximately $0.10.

How big of a company is ProMIS Neurosciences?

ProMIS Neurosciences has a market capitalization of $28.71 million.

What is ProMIS Neurosciences' official website?

The official website for ProMIS Neurosciences is www.promisneurosciences.com.

How can I contact ProMIS Neurosciences?

ProMIS Neurosciences' mailing address is 1920 Yonge Street Suite 200Suite 200, Toronto A6, M4S 3E2. The company can be reached via phone at 416 847 6898.

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.